Epizyme, Inc.
PRMT5 inhibitors and uses thereof
Last updated:
Abstract:
Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
Status:
Grant
Type:
Utility
Filling date:
4 Aug 2015
Issue date:
19 May 2020